Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus

Journal of the European Academy of Dermatology and Venereology : JEADV
Ulrich MrowietzR B Warren

Abstract

Fumaric acid esters (FAEs) are a group of small molecules that were first investigated for the treatment of psoriasis in 1959. The first fumarate-based drug - Fumaderm® - was approved in Germany in 1994 for severe psoriasis and then in 2008, the label was expanded to include moderate psoriasis. Fumaderm is a combination of different FAEs: dimethyl fumarate (DMF), which is regarded as the main active component, plus calcium, magnesium and zinc salts of monoethyl fumarate (MEF). FAEs are the most frequently used first-line systemic psoriasis treatment in Germany, with an overall treatment experience comprising more than 220 000 patient-years. FAEs have demonstrated good, sustained clinical efficacy with an acceptable safety profile for the long-term treatment of patients with moderate-to-severe psoriasis. Indeed, the European S3-Guideline on the systemic treatment of Psoriasis vulgaris recommends FAEs for induction and long-term treatment. Until recently, FAEs were only licensed (for the psoriasis indication) in Germany, but were imported to many other European countries, such as The Netherlands, UK, Ireland, Austria and Italy, for the treatment of psoriasis. In 2017, the European Medicines Agency (EMA) approved Skilarence® , a n...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Aug 23, 2003·The British Journal of Dermatology·J J HoefnagelJ N Bouwes Bavinck
Feb 3, 2004·The Journal of Dermatological Treatment·I CarboniS Chimenti
Apr 22, 2004·The British Journal of Dermatology·P BalasubramaniamJ Berth-Jones
Sep 18, 2004·British Journal of Clinical Pharmacology·Nicolle H R LitjensPeter H Nibbering
Sep 25, 2004·Journal of the American Academy of Dermatology·Richard G Langley, Charles N Ellis
May 13, 2005·The British Journal of Dermatology·A Y Finlay
Aug 27, 2005·The British Journal of Dermatology·M J HarriesC E M Griffiths
Oct 6, 2006·Archives of Dermatological Research·Ulrich MrowietzJonathan Barker
Jul 31, 2007·Lancet·Christopher Em Griffiths, Jonathan Nwn Barker
Jul 31, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Ulrich MrowietzWolfram Sterry
Aug 30, 2008·Clinics in Dermatology·Martin Rostami Yazdi, Ulrich Mrowietz
Sep 20, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Matthias AugustinMarc Radtke
Nov 22, 2008·Journal of the American Academy of Dermatology·Shanu Kohli Kurd, Joel M Gelfand
Oct 3, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·P SusitaivalM Bruze
Sep 22, 2010·Archives of Dermatological Research·U MrowietzN Yawalkar
Apr 20, 2011·Dermatology : International Journal for Clinical and Investigative Dermatology·S GerdesU Mrowietz
May 1, 2010·Future Virology·A Sami SaribasMahmut Safak
Jul 21, 2011·Clinical and Experimental Dermatology·S OgilvieJ Foerster
Mar 6, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·K Reich
May 3, 2012·Clinical and Experimental Dermatology·K Heelan, T Markham
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Jan 15, 2013·Journal of Clinical Epidemiology·Jeff AndrewsHolger J Schünemann
Feb 26, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Diamant ThaçiKristian Reich
Apr 11, 2013·Journal of Clinical Epidemiology·Jeffrey C AndrewsGordon Guyatt
Apr 26, 2013·The New England Journal of Medicine·Ummehan ErmisJörg B Schulz
Apr 26, 2013·The New England Journal of Medicine·Bob W van OostenMike P Wattjes
Apr 26, 2013·The New England Journal of Medicine·Marianne T SweetserCarmen Bozic
Jul 5, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·S Fallah AraniH B Thio
Sep 13, 2013·The New England Journal of Medicine·Ummehan ErmisJörg B Schulz
Sep 13, 2013·The New England Journal of Medicine·Ulrich Mrowietz, Kristian Reich
Sep 17, 2013·The New England Journal of Medicine·Marianne T SweetserCarmen Bozic
Dec 21, 2013·The Journal of Dermatological Treatment·Richard G B LangleyCharis Papavassilis
Jan 30, 2014·The British Journal of Dermatology·N IsmailA Lally
Apr 22, 2014·American Journal of Preventive Medicine·Charles G HelmickChristopher L Bartlett
May 13, 2014·Experimental Dermatology·Ulrich MrowietzSascha Gerdes
Sep 24, 2014·Dermatology : International Journal for Clinical and Investigative Dermatology·Kirsten SteinzUlrich Mrowietz
Feb 11, 2015·Dermatology : International Journal for Clinical and Investigative Dermatology·Dagmar Wilsmann-TheisSascha Gerdes
Apr 9, 2015·The New England Journal of Medicine·Thorsten RosenkranzChristoph Terborg

❮ Previous
Next ❯

Citations

Oct 27, 2018·American Journal of Clinical Dermatology·Chia-Yu LiuChing-Chi Chi
Aug 30, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·P C M van de KerkhofJ C Szepietowski
Feb 15, 2020·Biomolecules·Paulina HennigHans-Dietmar Beer
Mar 5, 2020·Expert Opinion on Drug Safety·Radomir Reszke, Jacek C Szepietowski
Jun 13, 2020·Dermatology and Therapy·Deepak M W BalakLaura Salgado-Boquete
Feb 7, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·A NastC Dressler
Oct 23, 2020·Pharmacology & Therapeutics·Cinzia Dello RussoMunir Pirmohamed
Feb 24, 2021·Trends in Pharmacological Sciences·Ayla HoogendoornPeter M Grace
Mar 19, 2021·Frontiers in Immunology·Cong QiJingxia Zhao
Jan 13, 2021·Journal of Clinical Pharmacy and Therapeutics·Paula Evelyn BeattyAnne Marie Tobin
Jul 9, 2021·Psoriasis : Targets and Therapy·Hakim Ben AbdallahLars Iversen
Dec 22, 2021·The Journal of Dermatological Treatment·Ralph von Kiedrowski, Sebastian Diemert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.